semaglutide deaths Recent study at UC Irvine found that medication may benefit 93 million U.S. adults Semaglutide reduces risk of all-cause

With the combined use of structure and medicinal chemistry, several groups have demonstrated that it is feasible to obtain small-molecule PTP1B inhibitors with the requisite potency and selectivity

The findings indicate that the effects of the medications needed to be monitored closely, the researchers said, stressing that changes could be made to help fight and potentially prevent these effects

Scientists are currently involved in developing extended-acting drugs to reduce the frequency of dosages and also developing oral GLP-1 drugs as an alternative to injectable ones

All studies were blinded and placebo-controlled